Osimertinib for neoplasm, residual

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Mar 2024: Trial registered, NCT06323148

The trials

NCT06323148: Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

State
Not started
Phase
Phase 3
People
226 planned
Started
1 Apr 2024
Primary completion
31 Mar 2026
Arms
ct-DNA-positive patients receiving adjuvant osimertinib
Results
None posted
  1. 21 Mar 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg, Osimertinib 80 mg/40 mg.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.